Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

Inclusion Criteria: 1. Healthy male aged 18 to 45 years (including both ends) at the time of signing the informed consent. 2. Weighing not less than 50kg，Body Mass Index (BMI)of 18 to 25kg/m2. 3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (Tbil) are within the normal range during screening; 4. Estimated creatinine clearance (Clcr) ≥90ml / min calculated by the Cockcroft-Gault (CG) formula ; 5. Capable of giving written informed consent, which included compliance with the requirements and restrictions listed in the consent form. Exclusion Criteria: 1. The hepatitis B surface antigen, hepatitis C antibody, HIV antibody test positive; 2. Having history of syncope, palpitations, bradycardia, tachycardia and other anomalies(such as the extent of any way block, left bundle branch block, right bundle branch block), or via a comprehensive physical examination (vital signs, physical examination), routine laboratory tests (blood count, blood biochemistry, urine, etc.), 12-lead ECG, abdominal B ultrasound (liver, gallbladder, pancreas, spleen, kidney), and other abnormalities and clinical significance persons before screening; 3. Having Alcohol and drug abuse within first 6 months before screening; 4. Smoked within 3 months before screening; 5. In screening period, blood pressure greater than 140 / 90mmHg, retest after diagnosis or pulse rate is higher than 100bpm person; 6. In screening period, ECG QTc\> 450ms,diagnosed after retest; 7. Having a history of drug or allergic reactions or allergic constitution have hypersensitivity to any of the following: 1\) digoxin and / or any of its ingredients or other similar drugs . 2) PEX168 8\. Before screening, having a history of cardiovascular disease (coronary heart disease, high blood pressure, high cholesterol, etc.) or a history of pulmonary disease (chronic bronchitis, emphysema, asthma, pneumonia, etc.); 9\. In screening period , fasting triglycerides test result was greater than the upper limit of normal range; 10\. Currently there is a history of liver disease or liver disease or a known hepatobiliary abnormalities (except asymptomatic gallstones); 11\. Participate in blood donation and donation amount ≥400ml within three months before screening, or who participate in blood donation or blood transfusion within a month; 12\. In screening period, having thyroid dysfunction or a history; 13\. The history of gastrointestinal surgery (such as stomach cutting surgery, gastric bypass surgery) before screening; 14\. The history of pancreatitis; 15\. History of cholecystitis gallbladder disease or other disease history; 16\. The history of inflammatory bowel disease or a history of irritable bowel syndrome; 17\. The history of Type 2 multiple endocrine neoplasia; 18\. The history of medullary thyroid cancer; 19\. The family has type 2 multiple endocrine fibromatosis or a history of medullary thyroid cancer; 20\. 3 months before screening, participating in any drug or medical device trials are (including placebo); 21\. Using any of the tested drugs may affect prescription drugs , non-prescription drugs, herbal (especially ginseng, oral hypoglycemic agents) or multivitamin supplements persons; 22\. Drinking medication or caffeine-containing xanthine food and beverage (listed in annex 3), strenuous exercise, or other effects of drug absorption, distribution, metabolism, excretion and other factors 2 days before screening. 23\. Received GLP-1 analogs (e.g. exenatide) treatment; 24\. Reluctant to take an effective method of contraception during the test, fertility planner within six months after his or her spouse during the test or the last dose (38 days); 25\. Researchers believe any situation that might lead to any subject cannot complete the study or to the subject of this study bring significant risk.